I. Šestak

发表

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

E. Mardis, C. Perou, M. Ellis, 2015, BMC Medical Genomics.

IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer.

I. Šestak, B. Shadbolt, R. Lakhanpal, 2016, Breast.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Jack Cuzick, Ivana Sestak, Mitch Dowsett, 2010, The Lancet. Oncology.

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

Jack Cuzick, Ivana Sestak, Mitch Dowsett, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

Jack Cuzick, Ivana Sestak, Mitch Dowsett, 2013, The Lancet. Oncology.

Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype.

R. Greil, J. Cuzick, T. Nielsen, 2013 .

Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial

J. Cuzick, K. Byth, M. Dowsett, 2015, Breast Cancer Research and Treatment.

Diffuse reflectance spectroscopy for field scale assessment of winter wheat yield

I. Šestak, M. Mesić, Ž. Zgorelec, 2017, Environmental Earth Sciences.

Effects of Agricultural Practices on Carbon Emission and Soil Health

Aleksandra Perčin, Milan Mesić, Ivana Šestak, 2019, Journal of Sustainable Development of Energy, Water and Environment Systems.

Carbon content and C/N ratio in Pannonian and Mediterranean soils

I. Šestak, I. Kisić, M. Mesić, 2012 .

Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial

J. Cuzick, A. Howell, R. Eastell, 2021, British Journal of Cancer.

Breast cancer chemoprevention

J. Cuzick, I. Šestak, 2011 .

Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.

J. Cuzick, J. Forbes, I. Šestak, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk stratification in early breast cancer in premenopausal and postmenopausal women: integrating genomic assays with clinicopathological features

I. Šestak, 2019, Current opinion in oncology.

Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.

J. Cuzick, A. Howell, J. Forbes, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy

I. Šestak, 2017, Breast Care.

Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor–Positive Lymph Node–Negative Early-Stage Breast Cancer

J. Cuzick, M. Dowsett, Yi Zhang, 2016, Clinical Cancer Research.

Cross-Strati fi cationandDifferential RiskbyBreast Cancer Index and Recurrence Score in Women with Hormone Receptor – Positive Lymph Node – Negative Early-Stage Breast Cancer

J. Cuzick, M. Dowsett, Yi Zhang, 2016 .

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial

J. Cuzick, A. Howell, J. Forbes, 2012, British Journal of Cancer.

Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer

J. Cuzick, A. Howell, J. Forbes, 2012, Breast Cancer Research and Treatment.

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.

J. Cuzick, A. Howell, J. Forbes, 2014, The Lancet. Oncology.

Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial.

J. Cuzick, A. Howell, J. Forbes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors

J. Cuzick, I. Šestak, 2016, Expert review of endocrinology & metabolism.

Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia

J. Cuzick, R. Eastell, I. Šestak, 2019, Bone.

Hyperspectral sensing of soil pH, total carbon and total nitrogen content based on linear and non-linear calibration methods

I. Šestak, M. Mesić, Ž. Zgorelec, 2019, Journal of Central European Agriculture.

Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer

Jack Cuzick, Ivana Sestak, Kalnisha Naidoo, 2018, Journal of the National Cancer Institute.

Soil Chemical Properties and Trace Elements after Wildfire in Mediterranean Croatia: Effect of Severity, Vegetation Type and Time-Since-Fire

I. Šestak, Domina Delač, Igor Bogunović, 2022, Agronomy.

Effects of fertilisation on radionuclide uptake by maize from an acidic soil in northwestern Croatia

I. Šestak, M. Mesić, Ž. Zgorelec, 2021 .

Sulphur cycling between terrestrial agroecosystem and atmosphere

I. Šestak, I. Kisić, F. Bašić, 2012, Arhiv za higijenu rada i toksikologiju.

Sulphur balance in agroecosystem.

I. Šestak, M. Mesić, Ž. Zgorelec, 2018 .

Beneficial Effect of Tamoxifen for Women with DCIS: Long-Term Results from the UK/ANZ DCIS Trial in Women with Locally Excised DCIS.

J. Cuzick, J. Forbes, I. Ellis, 2009 .

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

J. Cuzick, S. Cawthorn, A. Howell, 2014, The Lancet.

Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.

J. Cuzick, I. Šestak, F. Sapunar, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radioactivity of Selected Agricultural Soils in Croatia: Effects of Soil Properties, Soil Management, and Geological Parameters

I. Šestak, I. Kisić, M. Mesić, 2017, Water, Air, & Soil Pollution.

Abstract S6-05: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC

J. Cuzick, S. Ferree, M. Dowsett, 2017 .

Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification.

L. Pusztai, L. Carey, I. Šestak, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer

M. Dowsett, I. Šestak, A. Ring, 2020, Breast Cancer Research and Treatment.

Soil Carbon Variability in Some Hungarian and Croatian Soils

I. Šestak, I. Kisić, M. Mesić, 2014 .

Application of the self-calibrated palmer drought severity index and standardized precipitation index for estimation of drought impact on maize grain yield in Pannonian part of Croatia

I. Šestak, I. Pejić, K. Pandžić, 2022, Natural Hazards.

Cross-Strati ﬁ cation and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor – Positive Lymph Node – Negative Early-Stage Breast Cancer

J. Cuzick, M. Dowsett, Yi Zhang, 2016 .

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

J. Cuzick, A. Howell, J. Forbes, 2016, The Lancet.

54O_PRCOMPARISON OF FIVE DIFFERENT SCORES FOR THE PREDICTION OF LATE RECURRENCE FOR OESTROGEN RECEPTOR-POSITIVE BREAST CANCER

J. Cuzick, S. Ferree, M. Erlander, 2013 .

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

J. Cuzick, S. Cawthorn, A. Howell, 2015, The Lancet. Oncology.

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

A. LaCroix, S. Cummings, J. Cuzick, 2013, The Lancet.

Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review.

A. Howell, I. Šestak, J. Iqbal, 2012, Cancer treatment reviews.

Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials

J. Cuzick, A. Howell, T. Powles, 2016, Breast Cancer Research and Treatment.

Update on breast cancer risk prediction and prevention

J. Cuzick, I. Šestak, 2015, Current opinion in obstetrics & gynecology.

Markers for the identification of late breast cancer recurrence

J. Cuzick, I. Šestak, 2015, Breast Cancer Research.

Preventative therapies for healthy women at high risk of breast cancer

I. Šestak, 2014, Cancer management and research.

Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of αvβ6 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence

J. Cuzick, I. Šestak, G. Thomas, 2013, Clinical Cancer Research.

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial

J. Cuzick, J. Forbes, I. Ellis, 2010, The Lancet. Oncology.

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.

J. Cuzick, S. Cawthorn, A. Howell, 2007, Journal of the National Cancer Institute.

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.

J. Cuzick, J. Forbes, A. Buzdar, 2008, The Lancet. Oncology.

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials

Jack Cuzick, Adam R. Brentnall, Ivana Sestak, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors

J. Cuzick, S. Ferree, M. Dowsett, 2016, Breast Cancer Research and Treatment.

Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis

J. Wardle, R. Horne, J. Wardle, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

J. Cuzick, M. Dowsett, I. Šestak, 2012, Journal of the National Cancer Institute.

Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.

J. Cuzick, L. Fallowfield, D. Cella, 2008, The Lancet. Oncology.

Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study

J. Cuzick, J. Forbes, M. Dowsett, 2013, Breast Cancer Research and Treatment.

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer

J. Cuzick, S. Ferree, M. Dowsett, 2018, JAMA oncology.

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study

J. Cuzick, S. Ferree, M. Dowsett, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

J. Cuzick, A. Howell, M. Dowsett, 2020, Breast.

Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study

J. Cuzick, M. Dowsett, I. Šestak, 2019, Clinical Cancer Research.

IHC 4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer

I. Šestak, B. Shadbolt, R. Lakhanpal, 2016 .

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

J. Cuzick, M. Dowsett, C. Denkert, 2016, Journal of the National Cancer Institute.

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

J. Cuzick, W. Gradishar, M. Gnant, 2019, Breast Cancer Research and Treatment.

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.

H. Putter, J. Cuzick, J. Forbes, 2017, European journal of cancer.

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer

Jack Cuzick, Ivana Sestak, Mitch Dowsett, 2013, Journal of the National Cancer Institute.

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial

J. Cuzick, S. Cawthorn, A. Howell, 2019, The Lancet.

Impact of preventive therapy on the risk of breast cancer among women with benign breast disease

J. Cuzick, I. Šestak, M. Thorat, 2015, Breast.

Abstract GS4-03: Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study

R. Gray, J. Cuzick, M. Dowsett, 2020 .

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5

Jack Cuzick, Ivana Sestak, Mitch Dowsett, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Application of Phosphogypsum in Agriculture

I. Šestak, M. Mesić, Ž. Zgorelec, 2016 .

Nitrate-Nitrogen Content in Soil and Lysimeter Water under Different Nitrogen Fertilization Levels in Crop Production

I. Šestak, M. Mesić, Ž. Zgorelec, 2014 .

Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer

J. Cuzick, A. Howell, J. Forbes, 2015, Clinical Cancer Research.

Soil Chemical Properties and Fire Severity Assessment Using VNIR Proximal Spectroscopy in Fire-Affected Abandoned Orchard of Mediterranean Croatia

I. Šestak, P. Pereira, Igor Bogunović, 2022, Agronomy.

Wildfire Impacts on Soil Physical and Chemical Properties-A Short Review of Recent Studies

I. Šestak, Igor Bogunović, Iva Hrelja, 2020 .

Trajno motrenje ekosustava okoliša CPS Molve

I. Šestak, I. Kisić, F. Bašić, 2013 .

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer

J. Cuzick, M. Dowsett, A. Harris, 2009, Breast Cancer Research.

The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies

J. Cuzick, A. Howell, J. Forbes, 2021, Breast Cancer Research and Treatment.

ER and HER 2 expression are positively correlated in HER 2 non-overexpressing breast cancer

Hern, J. Cuzick, M. Dowsett, 2016 .

Mixed convection heat transfer in horizontal channel filled with nanofluids

I. Šestak, B. Jovanovic, 2013 .

Comparison of side-effect profiles during active treatment versus follow-up in the International Breast Cancer Intervention Study I tamoxifen prevention trial

J. Cuzick, A. Howell, I. Šestak, 2007, Breast Cancer Research.

Benefit of low‐dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS

M. Cazzaniga, B. Bonanni, I. Šestak, 2016, International journal of cancer.

Assessment of the Impact of Soil Contamination with Cadmium and Mercury on Leaf Nitrogen Content and Miscanthus Yield Applying Proximal Spectroscopy

I. Šestak, N. Bilandžija, Ž. Zgorelec, 2022, Agronomy.

Land use change and soil fertility assessment in the vicinity of Zagreb landfill

I. Šestak, M. Mesić, Ž. Zgorelec, 2018 .

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer

Jack Cuzick, Richard Buus, Ivana Sestak, 2018, Breast Cancer Research.

Prognostic Value of EndoPredict in Women with Hormone Receptor–Positive, HER2-Negative Invasive Lobular Breast Cancer

R. Greil, J. Cuzick, M. Dowsett, 2020, Clinical Cancer Research.

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)

J. Cuzick, A. Howell, J. Forbes, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

J Cuzick, R. Greil, J. Cuzick, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

The effect of behavioural risk factors on osteoporosis in Irish women

P. Jakeman, N. Murphy, I. Šestak, 2013, Irish Journal of Medical Science.

Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.

J. Cuzick, A. Howell, J. Forbes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

J. Cuzick, M. Dowsett, M. Cheang, 2021, npj Breast Cancer.

Abstract GS4-04: Ten year results of the international breast cancer intervention study II

J. Cuzick, S. Cawthorn, A. Howell, 2020 .

Effect of Body Mass Index on Recurrence in Hormone Receptor Positive Early Breast Cancer – A Retrospective Exploratory Analysis from the ATAC Trial.

J. Cuzick, J. Forbes, I. Šestak, 2009 .

Preventive Therapy for Breast Cancer

J. Cuzick, I. Šestak, 2012, Current Oncology Reports.

SOIL SAMPLING WITH NEW SOIL SAMPLING PROBE

I. Šestak, M. Mesić, Igor Bogunović, 2013 .

Winter wheat agronomic traits and nitrate leaching under variable nitrogen fertilization

Ivica Kisić, Ferdo Bašić, Milan Mesić, 2018 .

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

J. Cuzick, M. Dowsett, M. Cheang, 2021, NPJ breast cancer.

Abstract GS6-01: Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy

J. Cuzick, M. Dowsett, I. Šestak, 2018 .

Approximation of thermoelasticity contact problem with nonmonotone friction

I. Šestak, B. Jovanovic, 2010 .

Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II

J. Cuzick, A. Howell, J. Forbes, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract P2-10-15: Evaluation of Prognostic and Predictive Performance of Breast Cancer Index and Its Components in Hormonal Receptor-Positive Breast Cancer Patients: A TransATAC Study

J. Cuzick, M. Erlander, M. Dowsett, 2012 .

10-year analysis of the ATAC trial: wrong conclusion? – Authors' reply

J. Cuzick, A. Howell, J. Forbes, 2011 .

Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.

J. Cuzick, M. Dowsett, I. Šestak, 2022, European journal of cancer.

Recurrence Score in women with hormone receptor positive lymph-node 2 negative early stage breast cancer

Mitch, J. Cuzick, Yi Zhang, 2016 .

Cancer Index and Recurrence Score in Women with Hormone Receptor – Positive Lymph Node – Negative Early-Stage Breast Cancer

J. Cuzick, M. Dowsett, Yi Zhang, 2016 .

A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk

J. Cuzick, B. Bonanni, I. Šestak, 2021, Cancers.

P1-06-02: Correlation between Gene Variants in CYP19 (Aromatase) and TCL1A with Disease and Tolerability Endpoints in the ATAC Trial.

J. Cuzick, S. Pineda, M. Dowsett, 2011 .

Preventative therapies for healthy women at high risk of breast cancer.

I. Šestak, 2014 .

Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: Results from two randomized tamoxifen prevention trials.

J. Cuzick, A. Howell, T. Powles, 2014 .

Preventative therapies for healthy women at high risk of breast cancer

I. Šestak, 2014 .

Cancer Management and Research Dovepress Preventative Therapies for Healthy Women at High Risk of Breast Cancer

I. Šestak, 2022 .

Abstract S1-9: Comparative Performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the Prediction of Late Recurrence in Hormonal Receptor-Positive Lymph Node-Negative Breast Cancer Patients: A TransATAC Study

Dennis C. Sgroi, Jack Cuzick, Yi Zhang, 2012 .

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5

J. Cuzick, M. Dowsett, I. Šestak, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Horizontal and vertical nitrate-nitrogen distribution under different nitrogen fertilization levels

I. Šestak, M. Mesić, Ž. Zgorelec, 2013 .

Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.

J. Cuzick, L. Fallowfield, D. Cella, 2008, The Lancet. Oncology.

Application of the Self-calibrated Palmer Drought Severity Index for Estimation of Drought Impact on Maize Grain Yield in Pannonian Part of Croatia

Marija Pecina, Ivan Pejić, Nataša Strelec Mahović, 2021 .

Anastrozole for Prevention of Breast Cancer in High-risk Postmenopausal Women (ibis-ii): an International, Double-blind, Randomised Placebo- Controlled Trial Journal Title Copyright Statement Articles Anastrozole for Prevention of Breast Cancer in High-risk Postmenopausal Women (ibis-ii): an Interna

S. Cawthorn, I. Šestak, Jill Knox, 2022 .